Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Celcuity Inc. (CELC)
USD89.08
-21.97 (-19.78%)
US NASDAQ Healthcare Biotechnology
Address
16305 36th Avenue North 55446
Minneapolis, MN, US
Minneapolis, MN, US
CEO
Brian F. Sullivan
Website
celcuity.com
IPO
2017-09-19
CIK 1603454 ISIN US15102K1007
Description
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD89.08
-21.97 (-19.78%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.12
Float Shares
29.66M
Free Float %
61.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.23% | +3.07% | +11.48% | +28.91% | +45.36% | +35.07% | +1,140.52% | +1,306.26% | +400.63% | +842.76% | +842.76% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
89.08
Low
110.00
+23.5%
Consensus
151.71
+70.3%
Median
157.00
+76.2%
High
189.00
+112.2%
Ratings Trend (MoM)
92% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 10 | +1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 5 |
165.20
+85.5%
|
| Last Quarter | 8 |
149.88
+68.3%
|
| Last Year | 11 |
136.09
+52.8%
|
| All Time | 14 |
114.29
+28.3%
|
Quality scores
Altman Z-Score
8.99
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-33.6% Q1'26: -12.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+33.2% Q1'26: +26.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.13× Q1'26: -0.97× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 5 EPS Ana. |
Dec 2027 7 Rev. Ana. 4 EPS Ana. |
Dec 2028 7 Rev. Ana. 7 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 5.04M (-100.0%)
|
—
est: 1.22M (-100.0%)
|
57.21M
35.03M – 78.57M
+4,601.8% YoY
|
395.32M
228.38M – 614.49M
+591.1% YoY
|
751.15M
724.46M – 777.84M
+90.0% YoY
|
1.15B
587.44M – 1.88B
+53.1% YoY
|
1.56B
795.58M – 2.54B
+35.4% YoY
|
| EBITDA |
-101.37M
|
-172.19M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-101.50M
|
-172.19M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-111.78M
est: -127.16M (+12.1%)
|
-177.04M
est: -199.37M (+11.2%)
|
-209.05M
-272.28M – -172.68M
-4.9% YoY
|
25.17M
-174.29M – 178.21M
+112.0% YoY
|
299.40M
101.40M – 445.54M
+1,089.5% YoY
|
469.63M
170.87M – 854.32M
+56.9% YoY
|
602.48M
219.21M – 1.10B
+28.3% YoY
|
| SGA |
9.06M
|
27.20M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-2.83
est: -2.63 (-7.7%)
|
-3.78
est: -3.85 (+1.9%)
|
-3.99
-5.18 – -3.29
-3.4% YoY
|
0.06
-3.32 – 3.39
+101.6% YoY
|
4.71
1.93 – 8.48
+7,252.7% YoY
|
8.94
3.25 – 16.26
+90.0% YoY
|
11.47
4.17 – 20.86
+28.3% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | Needham | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
118
Total invested
583.57M
Insider transactions (90d)
2
Beneficial owners (>5%)
49
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BVF Inc. | 3.47M | 9.90% | — | — | — | 3.47M | CO | Delaware | 2024-06-10 | ↗ |
| 2 | BVF Partners L.P. | 3.47M | 9.90% | — | — | — | 3.47M | IA, PN | Delaware | 2024-06-10 | ↗ |
| 3 | Mark N. Lampert | 3.47M | 9.90% | — | — | — | 3.47M | IN | Delaware | 2024-06-10 | ↗ |
| 4 | BVF GP Holdings LLC | 3.26M | 9.30% | — | — | — | 3.26M | OO | Delaware | 2024-06-10 | ↗ |
| 5 | Baker Bros. Advisors (GP) LLC | 1.87M | 5.10% | 1.87M | — | 1.87M | — | HC, OO | Delaware | 2024-11-14 | ↗ |
| 6 | Baker Bros. Advisors LP | 1.87M | 5.10% | 1.87M | — | 1.87M | — | IA, PN | Delaware | 2024-11-14 | ↗ |
| 7 | Felix J. Baker | 1.87M | 5.10% | 1.87M | — | 1.87M | — | HC, IN | United States | 2024-11-14 | ↗ |
| 8 | Julian C. Baker | 1.87M | 5.10% | 1.87M | — | 1.87M | — | HC, IN | United States | 2024-11-14 | ↗ |
| 9 | BVF I GP LLC | 1.83M | 5.20% | — | — | — | 1.83M | OO | Delaware | 2024-06-10 | ↗ |
| 10 | Biotechnology Value Fund, L.P. | 1.83M | 5.20% | — | — | — | 1.83M | PN | Delaware | 2024-06-10 | ↗ |
| 11 | Koh, Bong | 1.66M | 9.99% | — | 1.66M | — | — | IN | United States | 2022-05-25 | ↗ |
| 12 | Shah, Nimish | 1.66M | 9.99% | — | 1.66M | — | — | IN | United States | 2022-05-25 | ↗ |
| 13 | VHCP Co-Investment Holdings II, LLC | 1.66M | 9.99% | — | 1.66M | — | — | OO | Delaware | 2022-05-25 | ↗ |
| 14 | VHCP Co-Investment Holdings III, LLC | 1.66M | 9.99% | — | 1.66M | — | — | OO | Delaware | 2022-05-25 | ↗ |
| 15 | VHCP Management EG, LLC | 1.66M | 9.99% | — | 1.66M | — | — | OO | Delaware | 2022-05-25 | ↗ |
| 16 | VHCP Management II, LLC | 1.66M | 9.99% | — | 1.66M | — | — | OO | Delaware | 2022-05-25 | ↗ |
| 17 | VHCP Management III, LLC | 1.66M | 9.99% | — | 1.66M | — | — | OO | Delaware | 2022-05-25 | ↗ |
| 18 | Venrock Healthcare Capital Partners EG, L.P. | 1.66M | 9.99% | — | 1.66M | — | — | PN | Delaware | 2022-05-25 | ↗ |
| 19 | Venrock Healthcare Capital Partners II, L.P. | 1.66M | 9.99% | — | 1.66M | — | — | PN | Delaware | 2022-05-25 | ↗ |
| 20 | Venrock Healthcare Capital Partners III, L.P. | 1.66M | 9.99% | — | 1.66M | — | — | PN | Delaware | 2022-05-25 | ↗ |
| 21 | Peter Kolchinsky | 1.49M | 9.90% | — | 1.49M | — | — | HC, IN | United States of America | 2022-05-25 | ↗ |
| 22 | RA Capital Healthcare Fund, L.P. | 1.49M | 9.90% | — | 1.49M | — | — | PN | Delaware | 2022-05-25 | ↗ |
| 23 | RA Capital Management, L.P. | 1.49M | 9.90% | — | 1.49M | — | — | IA, PN | Delaware | 2022-05-25 | ↗ |
| 24 | Rajeev Shah | 1.49M | 9.90% | — | 1.49M | — | — | HC, IN | United States of America | 2022-05-25 | ↗ |
| 25 | Joseph Edelman | 1.44M | 5.70% | — | 1.44M | — | 1.44M | IN | Delaware | 2023-12-26 | ↗ |
| 26 | Perceptive Advisors LLC | 1.44M | 5.70% | — | 1.44M | — | 1.44M | IA | Delaware | 2023-12-26 | ↗ |
| 27 | Perceptive Life Sciences Master Fund, Ltd. | 1.44M | 5.70% | — | 1.44M | — | 1.44M | CO | Delaware | 2023-12-26 | ↗ |
| 28 | BVF II GP LLC | 1.43M | 4.10% | — | — | — | 1.43M | OO | Delaware | 2024-06-10 | ↗ |
| 29 | Biotechnology Value Fund II, L.P. | 1.43M | 4.10% | — | — | — | 1.43M | PN | Delaware | 2024-06-10 | ↗ |
| 30 | Ali Behbahani | 1.25M | 8.40% | — | 1.25M | — | 1.25M | IN | States | 2022-05-24 | ↗ |
| 31 | Anthony A. Florence, Jr. | 1.25M | 8.40% | — | 1.25M | — | 1.25M | IN | States | 2022-05-24 | ↗ |
| 32 | Carmen Chang | 1.25M | 8.40% | — | 1.25M | — | 1.25M | IN | States | 2022-05-24 | ↗ |
| 33 | Edward T. Mathers | 1.25M | 8.40% | — | 1.25M | — | 1.25M | IN | States | 2022-05-24 | ↗ |
| 34 | Growth Equity Opportunities 18 VGE, LLC | 1.25M | 8.40% | — | 1.25M | — | 1.25M | OO | Delaware Limited Liability Company | 2022-05-24 | ↗ |
| 35 | Liza Landsman | 1.25M | 8.40% | — | 1.25M | — | 1.25M | IN | States | 2022-05-24 | ↗ |
| 36 | Mohamad H. Makhzoumi | 1.25M | 8.40% | — | 1.25M | — | 1.25M | IN | States | 2022-05-24 | ↗ |
| 37 | NEA 18 VGE GP, LLC | 1.25M | 8.40% | — | 1.25M | — | 1.25M | OO | Limited Liability Company | 2022-05-24 | ↗ |
| 38 | NEA 18 Venture Growth Equity, L.P. | 1.25M | 8.40% | — | 1.25M | — | 1.25M | PN | Delaware Limited Partnership | 2022-05-24 | ↗ |
| 39 | NEA Partners 18 VGE, L.P. | 1.25M | 8.40% | — | 1.25M | — | 1.25M | PN | Delaware Limited Partnership | 2022-05-24 | ↗ |
| 40 | Paul Walker | 1.25M | 8.40% | — | 1.25M | — | 1.25M | IN | States | 2022-05-24 | ↗ |
| 41 | Peter W. Sonsini | 1.25M | 8.40% | — | 1.25M | — | 1.25M | IN | States | 2022-05-24 | ↗ |
| 42 | Rick Yang | 1.25M | 8.40% | — | 1.25M | — | 1.25M | IN | States | 2022-05-24 | ↗ |
| 43 | Scott D. Sandell | 1.25M | 8.40% | — | 1.25M | — | 1.25M | IN | States | 2022-05-24 | ↗ |
| 44 | Morgan Stanley | 1.09M | 5.00% | 13.00 | 1.02M | — | 1.09M | HC, CO | — | 2023-02-08 | ↗ |
| 45 | Master Fund, L.P. | 604.6K | 4.00% | — | 604.6K | — | 604.6K | FI | Delaware | 2022-05-18 | ↗ |
| 46 | Equity Fund II, L.P. | 343.8K | 2.30% | — | 343.8K | — | 343.8K | PN | Delaware | 2022-05-18 | ↗ |
| 47 | LLC | 343.8K | 2.30% | — | 343.8K | — | 343.8K | OO | Delaware | 2022-05-18 | ↗ |
| 48 | BVF Partners OS Ltd. | 148.5K | 1.00% | — | — | — | 148.5K | CO | Delaware | 2024-06-10 | ↗ |
| 49 | Biotechnology Value Trading Fund OS LP | 148.5K | 1.00% | — | — | — | 148.5K | PN | Delaware | 2024-06-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
118
-133 vs prev Q
New positions
39
Closed positions
164
Increased
75
Reduced
25
Put/Call ratio
0.00
Calls held
45.00
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 7.92M +— (+0.0%) | 789.52M +398.5M (+101.9%) | 17.68% -0.454 pp | 4.62% +1.797 pp | USD24.71 +303.6% | 10 qtrs — |
| 2 | NEA MANAGEMENT COMPANY, LLC | 3.54M +1.4M (+64.9%) | 352.64M +246.7M (+232.9%) | 7.89% +2.984 pp | 17.98% +12.168 pp | USD47.56 +109.7% | 13 qtrs — |
| 3 | PERCEPTIVE ADVISORS LLC | 3.16M +203.9K (+6.9%) | 315.20M +169.2M (+115.8%) | 7.06% +0.286 pp | 5.62% +1.401 pp | USD35.84 +178.3% | 9 qtrs — |
| 4 | AVORO CAPITAL ADVISORS LLC | 3.11M +3.1M (+100.0%) | 310.30M +310.3M (+100.0%) | 6.95% +6.947 pp | 2.98% +2.983 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 5 | BLACKROCK, INC. | 2.54M +293.9K (+13.1%) | 253.38M +142.4M (+128.3%) | 5.67% +0.527 pp | 0.00% +0.002 pp | USD26.80 +272.2% | 6 qtrs — |
| 6 | VANGUARD GROUP INC | 2.28M +220.4K (+10.7%) | 227.35M +125.6M (+123.5%) | 5.09% +0.374 pp | 0.00% +0.002 pp | USD30.06 +231.8% | 33 qtrs — |
| 7 | SOLEUS CAPITAL MANAGEMENT, L.P. | 1.81M +629.4K (+53.4%) | 180.36M +122.1M (+209.7%) | 4.04% +1.338 pp | 6.65% +3.721 pp | USD42.95 +132.2% | 19 qtrs — |
| 8 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1.71M +980.5K (+133.7%) | 170.95M +134.7M (+371.8%) | 3.83% +2.147 pp | 2.18% +1.630 pp | USD78.20 +27.5% | 2 qtrs — |
| 9 | STATE STREET CORP | 1.64M +914.9K (+126.6%) | 163.34M +127.6M (+357.5%) | 3.66% +2.001 pp | 0.01% +0.004 pp | USD65.04 +53.4% | 19 qtrs — |
| 10 | MORGAN STANLEY | 1.40M -113.9K (-7.5%) | 139.53M +64.8M (+86.7%) | 3.12% -0.341 pp | 0.01% +0.004 pp | USD30.08 +231.6% | 34 qtrs — |
| 11 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.24M +642.1K (+107.4%) | 123.71M +94.2M (+318.6%) | 2.77% +1.400 pp | 0.01% +0.010 pp | USD75.01 +33.0% | 5 qtrs — |
| 12 | TANG CAPITAL MANAGEMENT LLC | 1.05M -100.0K (-8.7%) | 104.73M +47.9M (+84.3%) | 2.34% -0.289 pp | 5.17% +2.987 pp | USD49.40 +101.9% | 2 qtrs — |
| 13 | BANK OF AMERICA CORP /DE/ | 977.1K +437.6K (+81.1%) | 97.46M +70.8M (+265.7%) | 2.18% +0.946 pp | 0.01% +0.005 pp | USD63.66 +56.7% | 19 qtrs — |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 830.7K +64.2K (+8.4%) | 82.87M +45.0M (+118.8%) | 1.85% +0.099 pp | 0.01% +0.003 pp | USD24.69 +304.0% | 31 qtrs — |
| 15 | HOLOCENE ADVISORS, LP | 695.3K +695.3K (+100.0%) | 69.35M +69.4M (+100.0%) | 1.55% +1.553 pp | 0.15% +0.146 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 16 | GOLDMAN SACHS GROUP INC | 652.8K +229.9K (+54.4%) | 65.11M +44.2M (+211.6%) | 1.46% +0.489 pp | 0.01% +0.005 pp | USD64.36 +55.0% | 12 qtrs — |
| 17 | APIS CAPITAL ADVISORS, LLC | 602.0K -174.0K (-22.4%) | 60.04M +21.7M (+56.6%) | 1.34% -0.433 pp | 10.46% +1.995 pp | USD49.40 +101.9% | 2 qtrs — |
| 18 | RTW INVESTMENTS, LP | 550.2K +550.2K (+100.0%) | 54.87M +54.9M (+100.0%) | 1.23% +1.228 pp | 0.55% +0.550 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 19 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 546.6K -39.3K (-6.7%) | 54.52M +25.6M (+88.4%) | 1.22% -0.121 pp | 0.08% +0.041 pp | USD26.56 +275.5% | 7 qtrs — |
| 20 | NEARWATER CAPITAL MARKETS, LTD | 520.2K +520.2K (+100.0%) | 51.88M +51.9M (+100.0%) | 1.16% +1.162 pp | 0.89% +0.887 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 21 | CAPTION MANAGEMENT, LLC | 516.8K +189.1K (+57.7%) | 51.55M +35.4M (+218.4%) | 1.15% +0.403 pp | 0.35% +0.227 pp | USD67.82 +47.1% | 2 qtrs — |
| 22 | SIO CAPITAL MANAGEMENT, LLC | 477.1K -309.5K (-39.3%) | 47.58M +8.7M (+22.5%) | 1.07% -0.736 pp | 7.48% -2.348 pp | USD49.40 +101.9% | 2 qtrs — |
| 23 | CANDRIAM S.C.A. | 476.4K +85.4K (+21.9%) | 47.52M +28.2M (+146.0%) | 1.06% +0.168 pp | 0.24% +0.136 pp | USD38.34 +160.1% | 5 qtrs — |
| 24 | ALLIANCEBERNSTEIN L.P. | 472.9K -179.7K (-27.5%) | 47.17M +14.9M (+46.3%) | 1.06% -0.439 pp | 0.01% +0.005 pp | USD47.94 +108.1% | 7 qtrs — |
| 25 | SILVERARC CAPITAL MANAGEMENT, LLC | 375.1K +286.4K (+323.0%) | 37.42M +33.0M (+754.0%) | 0.84% +0.635 pp | 5.20% +4.606 pp | USD87.84 +13.5% | 2 qtrs — |
| 26 | WELLINGTON MANAGEMENT GROUP LLP | 371.1K +259.9K (+233.5%) | 37.02M +31.5M (+573.4%) | 0.83% +0.574 pp | 0.01% +0.006 pp | USD75.01 +33.0% | 6 qtrs — |
| 27 | CAPITOLIS LIQUID GLOBAL MARKETS LLC | 355.2K +355.2K (+100.0%) | 35.43M +35.4M (+100.0%) | 0.79% +0.793 pp | 0.21% +0.211 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 28 | PFIZER INC | 349.4K +— (+0.0%) | 34.85M +17.6M (+101.9%) | 0.78% -0.020 pp | 14.74% +10.792 pp | USD13.09 +662.0% | 5 qtrs — |
| 29 | SATURN V CAPITAL MANAGEMENT LLC | 317.1K -156.7K (-33.1%) | 31.63M +8.2M (+35.1%) | 0.71% -0.377 pp | 5.80% +0.671 pp | USD15.60 +539.4% | 7 qtrs — |
| 30 | EVENTIDE ASSET MANAGEMENT, LLC | 313.7K -775.1K (-71.2%) | 31.29M -22.5M (-41.8%) | 0.70% -1.793 pp | 0.49% -0.396 pp | USD19.76 +404.8% | 8 qtrs — |
| 31 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 307.3K +121.7K (+65.6%) | 30.65M +21.5M (+234.3%) | 0.69% +0.261 pp | 0.00% +0.003 pp | USD64.62 +54.3% | 8 qtrs — |
| 32 | SOFINNOVA INVESTMENTS, INC. | 299.4K +46.0K (+18.2%) | 29.86M +17.3M (+138.6%) | 0.67% +0.088 pp | 1.29% +0.603 pp | USD57.14 +74.6% | 2 qtrs — |
| 33 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 292.3K +23.6K (+8.8%) | 29.16M +15.9M (+119.6%) | 0.65% +0.037 pp | 0.00% +0.002 pp | USD25.38 +293.0% | 11 qtrs — |
| 34 | NORTHERN TRUST CORP | 287.7K +11.6K (+4.2%) | 28.70M +15.1M (+110.4%) | 0.64% +0.010 pp | 0.00% +0.002 pp | USD19.22 +418.9% | 33 qtrs — |
| 35 | DRIEHAUS CAPITAL MANAGEMENT LLC | 250.1K +87.8K (+54.1%) | 24.94M +16.9M (+211.2%) | 0.56% +0.187 pp | 0.17% +0.112 pp | USD67.08 +48.7% | 2 qtrs — |
| 36 | COLONY GROUP, LLC | 234.8K -36.0 (0.0%) | 23.42M +11.8M (+101.9%) | 0.52% -0.014 pp | 0.03% +0.008 pp | USD49.40 +101.9% | 2 qtrs — |
| 37 | JENNISON ASSOCIATES LLC | 229.7K +229.7K (+100.0%) | 22.91M +22.9M (+100.0%) | 0.51% +0.513 pp | 0.01% +0.014 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 38 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 226.5K +226.5K (+100.0%) | 22.59M +22.6M (+100.0%) | 0.51% +0.506 pp | 0.08% +0.076 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 39 | BOXER CAPITAL MANAGEMENT, LLC | 225.0K +135.0K (+150.0%) | 22.44M +18.0M (+404.8%) | 0.50% +0.296 pp | 4.91% +3.495 pp | USD79.60 +25.3% | 2 qtrs — |
| 40 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 221.6K +221.6K (+100.0%) | 22.10M +22.1M (+100.0%) | 0.49% +0.495 pp | 0.04% +0.037 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 41 | QUBE RESEARCH & TECHNOLOGIES LTD | 208.5K +201.8K (+3,028.4%) | 20.80M +20.5M (+6,216.2%) | 0.47% +0.450 pp | 0.02% +0.021 pp | USD98.13 +1.6% | 2 qtrs — |
| 42 | JANE STREET GROUP, LLC | 206.1K +206.1K (+100.0%) | 20.56M +20.6M (+100.0%) | 0.46% +0.460 pp | 0.00% +0.003 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 43 | HENNION & WALSH ASSET MANAGEMENT, INC. | 190.9K +19.6K (+11.4%) | 19.04M +10.6M (+125.0%) | 0.43% +0.034 pp | 0.66% +0.351 pp | USD22.77 +338.0% | 7 qtrs — |
| 44 | LORD, ABBETT & CO. LLC | 181.5K -66.4K (-26.8%) | 18.10M +5.9M (+47.8%) | 0.41% -0.163 pp | 0.06% +0.019 pp | USD49.40 +101.9% | 2 qtrs — |
| 45 | WALLEYE CAPITAL LLC | 153.3K -145.6K (-48.7%) | 15.29M +523.3K (+3.5%) | 0.34% -0.342 pp | 0.05% -0.009 pp | USD49.40 +101.9% | 2 qtrs — |
| 46 | ENSIGN PEAK ADVISORS, INC | 149.0K +149.0K (+100.0%) | 14.86M +14.9M (+100.0%) | 0.33% +0.333 pp | 0.03% +0.026 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 47 | INVESCO LTD. | 147.9K +6.9K (+4.9%) | 14.76M +7.8M (+111.8%) | 0.33% +0.007 pp | 0.00% +0.001 pp | USD51.76 +92.7% | 2 qtrs — |
| 48 | BNP PARIBAS ARBITRAGE, SNC | 142.2K -36.6K (-20.5%) | 14.18M +5.3M (+60.5%) | 0.32% -0.092 pp | 0.01% +0.002 pp | USD48.88 +104.1% | 33 qtrs — |
| 49 | WELLS FARGO & COMPANY/MN | 138.4K +116.1K (+520.0%) | 13.81M +12.7M (+1,151.9%) | 0.31% +0.258 pp | 0.00% +0.002 pp | USD87.72 +13.7% | 33 qtrs — |
| 50 | WOODLINE PARTNERS LP | 130.9K +130.9K (+100.0%) | 13.06M +13.1M (+100.0%) | 0.29% +0.292 pp | 0.05% +0.051 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 51 | AMERIPRISE FINANCIAL INC | 123.3K +61.8K (+100.7%) | 12.29M +9.3M (+305.2%) | 0.28% +0.135 pp | 0.00% +0.002 pp | USD55.87 +78.5% | 11 qtrs — |
| 52 | BARCLAYS PLC | 122.9K +69.2K (+129.2%) | 12.25M +11.5M (+1,433.1%) | 0.27% +0.152 pp | 0.00% +0.003 pp | USD62.31 +60.1% | 11 qtrs — |
| 53 | PATIENT SQUARE CAPITAL LP | 120.0K +20.0K (+20.0%) | 11.97M +7.0M (+142.3%) | 0.27% +0.039 pp | 2.56% +1.241 pp | USD57.79 +72.6% | 2 qtrs — |
| 54 | RAYMOND JAMES FINANCIAL INC | 119.6K -1.3K (-1.1%) | 11.95M +6.0M (+100.0%) | 0.27% -0.010 pp | 0.00% +0.002 pp | USD49.15 +102.9% | 3 qtrs — |
| 55 | STEMPOINT CAPITAL LP | 118.3K -18.4K (-13.4%) | 11.80M +5.0M (+74.8%) | 0.26% -0.049 pp | 2.02% +0.671 pp | USD49.40 +101.9% | 2 qtrs — |
| 56 | CLEARBRIDGE INVESTMENTS, LLC | 106.9K -27.3K (-20.3%) | 10.67M +4.0M (+60.9%) | 0.24% -0.069 pp | 0.01% +0.004 pp | USD49.40 +101.9% | 2 qtrs — |
| 57 | IKARIAN CAPITAL, LLC | 105.5K +105.5K (+100.0%) | 10.53M +10.5M (+100.0%) | 0.24% +0.236 pp | 0.82% +0.822 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 58 | VOYA INVESTMENT MANAGEMENT LLC | 105.0K +61.6K (+141.8%) | 10.47M +8.3M (+388.2%) | 0.23% +0.135 pp | 0.01% +0.008 pp | USD78.92 +26.4% | 2 qtrs — |
| 59 | TD ASSET MANAGEMENT INC | 97.5K +24.7K (+34.0%) | 9.73M +6.1M (+170.5%) | 0.22% +0.051 pp | 0.01% +0.005 pp | USD62.16 +60.5% | 2 qtrs — |
| 60 | BANK OF NEW YORK MELLON CORP | 88.6K +3.8K (+4.5%) | 8.84M +4.6M (+111.0%) | 0.20% +0.004 pp | 0.00% +0.001 pp | USD23.94 +316.6% | 11 qtrs — |
| 61 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 87.0K +37.8K (+76.6%) | 8.68M +6.2M (+256.6%) | 0.19% +0.082 pp | 0.37% +0.272 pp | USD71.24 +40.0% | 2 qtrs — |
| 62 | RUSSELL INVESTMENTS GROUP, LTD. | 85.8K -22.2K (-20.6%) | 8.56M +3.2M (+60.3%) | 0.19% -0.056 pp | 0.01% +0.003 pp | USD49.34 +102.1% | 8 qtrs — |
| 63 | ORBIMED ADVISORS LLC | 85.7K +1.6K (+2.0%) | 8.54M +4.4M (+105.9%) | 0.19% -0.001 pp | 0.18% +0.077 pp | USD50.37 +98.0% | 2 qtrs — |
| 64 | ATOM INVESTORS LP | 85.6K +85.6K (+100.0%) | 8.54M +8.5M (+100.0%) | 0.19% +0.191 pp | 0.68% +0.678 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 65 | NUVEEN, LLC | 85.3K -106.0K (-55.4%) | 8.51M -943.7K (-10.0%) | 0.19% -0.248 pp | 0.00% 0.000 pp | USD37.92 +163.0% | 4 qtrs — |
| 66 | MILLENNIUM MANAGEMENT LLC | 82.2K -444.4K (-84.4%) | 8.20M -17.8M (-68.5%) | 0.18% -1.022 pp | 0.00% -0.008 pp | USD43.39 +129.9% | 8 qtrs — |
| 67 | UBS GROUP AG | 81.6K -772.9K (-90.5%) | 8.14M -34.1M (-80.7%) | 0.18% -1.775 pp | 0.00% -0.005 pp | USD45.90 +117.3% | 34 qtrs — |
| 68 | NAN FUNG TRINITY (HK) LTD | 80.8K +80.8K (+100.0%) | 8.06M +8.1M (+100.0%) | 0.18% +0.180 pp | 0.64% +0.638 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 69 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 80.0K +80.0K (+100.0%) | 7.98M +8.0M (+100.0%) | 0.18% +0.179 pp | 0.40% +0.396 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 70 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 71.7K +14.7K (+25.8%) | 7.16M +4.3M (+154.3%) | 0.16% +0.030 pp | 0.01% +0.004 pp | USD53.85 +85.2% | 5 qtrs — |
| 71 | ACT CAPITAL MANAGEMENT, LLC | 63.4K +63.4K (+100.0%) | 6.33M +6.3M (+100.0%) | 0.14% +0.142 pp | 5.11% +5.114 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 72 | MAN GROUP PLC | 62.5K +62.5K (+100.0%) | 6.23M +6.2M (+100.0%) | 0.14% +0.140 pp | 0.01% +0.011 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 73 | CAPTRUST FINANCIAL ADVISORS | 61.5K -6.0K (-8.9%) | 6.14M +2.8M (+84.0%) | 0.14% -0.017 pp | 0.01% +0.005 pp | USD10.14 +883.6% | 23 qtrs — |
| 74 | CITADEL ADVISORS LLC | 58.0K +33.2K (+133.9%) | 5.78M +4.6M (+372.2%) | 0.13% +0.073 pp | 0.00% +0.001 pp | USD78.22 +27.5% | 13 qtrs — |
| 75 | D. E. SHAW & CO., INC. | 57.7K -314.3K (-84.5%) | 5.75M -12.6M (-68.7%) | 0.13% -0.723 pp | 0.00% -0.007 pp | USD49.40 +101.9% | 2 qtrs — |
| 76 | RAFFERTY ASSET MANAGEMENT, LLC | 57.1K +49.1K (+609.4%) | 5.70M +5.3M (+1,332.3%) | 0.13% +0.109 pp | 0.02% +0.018 pp | USD92.64 +7.7% | 2 qtrs — |
| 77 | SQUAREPOINT OPS LLC | 57.1K +57.1K (+100.0%) | 5.69M +5.7M (+100.0%) | 0.13% +0.127 pp | 0.01% +0.006 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 78 | GAGNON SECURITIES LLC | 53.4K -554.0 (-1.0%) | 5.33M +2.7M (+99.8%) | 0.12% -0.004 pp | 1.08% +0.550 pp | USD10.01 +896.4% | 34 qtrs — |
| 79 | BI ASSET MANAGEMENT FONDSMAEGLERSELSKAB A/S | 51.2K +51.2K (+100.0%) | 5.10M +5.1M (+100.0%) | 0.11% +0.114 pp | 0.05% +0.045 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 80 | JPMORGAN CHASE & CO | 51.1K -986.0 (-1.9%) | 5.09M +2.5M (+98.1%) | 0.11% -0.005 pp | 0.00% +0.000 pp | USD40.85 +144.2% | 13 qtrs — |
| 81 | NEW YORK STATE COMMON RETIREMENT FUND | 48.7K +1.0K (+2.1%) | 4.86M +2.5M (+106.1%) | 0.11% -0.001 pp | 0.01% +0.003 pp | USD30.78 +224.0% | 11 qtrs — |
| 82 | EAM INVESTORS, LLC | 48.0K -39.3K (-45.0%) | 4.79M +548.1K (+12.9%) | 0.11% -0.093 pp | 0.53% +0.047 pp | USD49.40 +101.9% | 2 qtrs — |
| 83 | AQUATIC CAPITAL MANAGEMENT LLC | 45.7K -23.1K (-33.5%) | 4.56M +1.2M (+34.2%) | 0.10% -0.056 pp | 0.13% +0.066 pp | USD49.40 +101.9% | 2 qtrs — |
| 84 | HARVEST INVESTMENT SERVICES, LLC | 42.5K +13.6K (+47.1%) | 4.24M +2.8M (+197.0%) | 0.09% +0.029 pp | 0.80% +0.513 pp | USD65.52 +52.2% | 2 qtrs — |
| 85 | HEALTHINVEST PARTNERS AB | 41.8K +4.7K (+12.6%) | 4.17M +4.0M (+2,041.0%) | 0.09% +0.008 pp | 1.33% +0.609 pp | USD55.02 +81.3% | 2 qtrs — |
| 86 | VICTORY CAPITAL MANAGEMENT INC | 41.5K +2.2K (+5.6%) | 4.14M +2.2M (+113.2%) | 0.09% +0.003 pp | 0.00% +0.001 pp | USD52.06 +91.6% | 2 qtrs — |
| 87 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 40.0K -18.9K (-32.1%) | 3.99M +1.1M (+37.1%) | 0.09% -0.046 pp | 0.03% +0.002 pp | USD49.40 +101.9% | 2 qtrs — |
| 88 | PRUDENTIAL FINANCIAL INC | 38.7K +34.5K (+817.9%) | 3.86M +3.7M (+1,753.3%) | 0.09% +0.077 pp | 0.00% +0.004 pp | USD94.26 +5.8% | 2 qtrs — |
| 89 | RHUMBLINE ADVISERS | 38.1K -3.3K (-8.1%) | 3.80M +1.8M (+85.6%) | 0.09% -0.010 pp | 0.00% +0.001 pp | USD12.86 +675.6% | 11 qtrs — |
| 90 | ALPS ADVISORS INC | 37.9K +17.8K (+89.0%) | 3.78M +2.8M (+281.6%) | 0.08% +0.039 pp | 0.02% +0.017 pp | USD55.69 +79.1% | 7 qtrs — |
| 91 | JNBA FINANCIAL ADVISORS | 36.8K -1.0K (-2.6%) | 3.67M +1.8M (+96.6%) | 0.08% -0.004 pp | 0.32% +0.151 pp | USD20.33 +390.6% | 34 qtrs — |
| 92 | EXOME ASSET MANAGEMENT LLC | 34.3K +34.3K (+100.0%) | 3.42M +3.4M (+100.0%) | 0.08% +0.077 pp | 1.64% +1.635 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 93 | BOOTHBAY FUND MANAGEMENT, LLC | 30.3K +30.3K (+100.0%) | 3.03M +3.0M (+100.0%) | 0.07% +0.068 pp | 0.05% +0.045 pp | USD99.74 +0.0% | 1 qtrs NEW |
| 94 | NEOS INVESTMENT MANAGEMENT LLC | 28.2K +2.4K (+9.5%) | 2.82M +1.5M (+121.0%) | 0.06% +0.004 pp | 0.02% +0.007 pp | USD30.24 +229.8% | 4 qtrs — |
| 95 | TEMA ETFS LLC | 27.8K +2.0K (+7.9%) | 2.77M +1.5M (+117.8%) | 0.06% +0.003 pp | 0.22% +0.110 pp | USD29.21 +241.5% | 4 qtrs — |
| 96 | ACCREDITED INVESTORS INC. | 27.1K +— (+0.0%) | 2.70M +1.4M (+101.9%) | 0.06% -0.002 pp | 0.14% +0.069 pp | USD23.62 +322.3% | 31 qtrs — |
| 97 | FMR LLC | 26.7K +23.6K (+786.3%) | 2.66M +2.5M (+1,689.3%) | 0.06% +0.053 pp | 0.00% +0.000 pp | USD90.40 +10.3% | 11 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 85 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Tema Oncology ETF CANC | 2.29% | 3.25M | 0.75% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 1.13% | 404.1K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 1.12% | 121.71M | 0.35% |
| 4 | Virtus Biotech Clinical Trials ETF BBC | 0.75% | 430.4K | 0.65% |
| 5 | American Century Small Cap Growth Insights ETF ACSG | 0.44% | 110.5K | 0.49% |
| 6 | iShares Russell 2000 Growth ETF IWO | 0.25% | 38.31M | 0.24% |
| 7 | Vanguard Russell 2000 Growth ETF VTWG | 0.24% | 4.13M | 0.06% |
| 8 | Pacer WealthShield ETF PWS | 0.23% | 56.2K | 0.60% |
| 9 | Strive Small-Cap ETF STXK | 0.21% | 161.8K | 0.18% |
| 10 | Federated Hermes MDT Small Cap Core ETF FSCC | 0.21% | 337.7K | 0.51% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.11
Bearish
Ratio by volume
0.17
Bearish
Buys
1
Sells
9
Shares acquired
9.0K
Shares disposed
53.0K
Cash buys
—
Cash sales
7.00
Net activity
-44,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Dalvey David | Director | S-Sale | D | Common Stock | 25,000 | 140.68 | 3.52M | 65,000 | I | ↗ |
| 2026-05-04 | Buller Richard E | Director | M-Exempt | A | Common Stock | 9,000 | 5.10 | 45.9K | 15,760 | I | ↗ |
| 2026-04-09 | NIGON RICHARD | Director | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 79,035 | D | ↗ |
| 2026-03-31 | Buller Richard E | Director | M-Exempt | A | Common Stock | 3,000 | 5.10 | 15.3K | 9,760 | I | ↗ |
| 2026-02-11 | ROMP CHARLES R | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-27 | Dalvey David | Director | S-Sale | D | Common Stock | 20,000 | 120.03 | 2.40M | 90,000 | I | ↗ |
| 2025-12-15 | NIGON RICHARD | Director | G-Gift | D | Common Stock | 19,975 | 0.00 | — | 89,035 | D | ↗ |
| 2025-12-05 | Buller Richard E | Director | M-Exempt | A | Common Stock | 3,000 | 5.50 | 16.5K | 9,760 | I | ↗ |
| 2025-12-04 | Furcht Leo | Director | M-Exempt | A | Common Stock | 250 | 7.60 | 1.9K | 11,000 | D | ↗ |
| 2025-12-02 | Buller Richard E | Director | G-Gift | D | Common Stock | 500 | 0.00 | — | 6,760 | I | ↗ |
| 2025-12-01 | Buller Richard E | Director | S-Sale | D | Common Stock | 1,100 | 98.13 | 107.9K | 7,260 | I | ↗ |
| 2025-11-21 | Dalvey David | Director | S-Sale | D | Common Stock | 15,000 | 100.00 | 1.50M | 110,000 | I | ↗ |
| 2025-11-20 | Buller Richard E | Director | M-Exempt | D | Stock Option (right to buy) | 3,900 | 14.83 | 57.8K | 2,622 | I | ↗ |
| 2025-11-19 | Buller Richard E | Director | G-Gift | D | Common Stock | 500 | 0.00 | — | 7,260 | I | ↗ |
| 2025-09-11 | NIGON RICHARD | Director | X-InTheMoney | A | Common Stock | 4,672 | 7.56 | 35.3K | 105,765 | D | ↗ |
| 2025-09-08 | BAKER BROS. ADVISORS LP | 10% Owner | P-Purchase | A | Common Stock | 151,524 | 56.22 | 8.52M | 7,207,272 | I | ↗ |
| 2025-09-02 | Sullivan Brian F. | Director / Officer | X-InTheMoney | A | Common Stock | 104,340 | 8.05 | 839.9K | 1,370,199 | D | ↗ |
| 2025-08-18 | Sullivan Brian F. | Director / Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 51.57 | 12.89M | 250,000 | D | ↗ |
| 2025-08-18 | Laing Lance G. | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 51.57 | 5.16M | 100,000 | D | ↗ |
| 2025-08-18 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 51.57 | 4.13M | 80,000 | D | ↗ |
| 2025-08-01 | BAKER BROS. ADVISORS LP | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 689,944 | I | ↗ |
| 2025-07-28 | Dalvey David | Director | S-Sale | D | Common Stock | 2,025 | 46.05 | 93.3K | 0 | D | ↗ |
| 2025-05-28 | Murphy Polly A. | Director | G-Gift | A | Stock Option (right to buy) | 8,153 | 14.83 | 120.9K | 8,153 | I | ↗ |
| 2025-05-28 | Buller Richard E | Director | G-Gift | A | Stock Option (right to buy) | 6,522 | 14.83 | 96.7K | 6,522 | I | ↗ |
| 2025-05-27 | Buller Richard E | Director | G-Gift | A | Common Stock | 1,079 | 0.00 | — | 7,760 | I | ↗ |
| 2025-05-19 | NIGON RICHARD | Director | A-Award | A | Stock Option (right to buy) | 14,048 | 10.69 | 150.2K | 14,048 | D | ↗ |
| 2025-05-19 | Murphy Polly A. | Director | A-Award | A | Stock Option (right to buy) | 14,048 | 10.69 | 150.2K | 14,048 | D | ↗ |
| 2025-05-19 | Furcht Leo | Director | A-Award | A | Stock Option (right to buy) | 14,048 | 10.69 | 150.2K | 14,048 | D | ↗ |
| 2025-05-19 | Dalvey David | Director | A-Award | A | Stock Option (right to buy) | 14,048 | 10.69 | 150.2K | 14,048 | D | ↗ |
| 2025-05-19 | Buller Richard E | Director | A-Award | A | Common Stock | 1,029 | 0.00 | — | 2,108 | D | ↗ |
| 2025-04-14 | Sullivan Brian F. | Director / Officer | G-Gift | A | Common Stock | 8,155 | 0.00 | — | 1,265,859 | D | ↗ |
| 2025-03-04 | Sullivan Brian F. | Director / Officer | G-Gift | A | Common Stock | 36,845 | 0.00 | — | 802,742 | I | ↗ |
| 2025-03-03 | Sullivan Brian F. | Director / Officer | G-Gift | D | Common Stock | 39,670 | 0.00 | — | 1,302,704 | D | ↗ |
| 2025-02-13 | Laing Lance G. | Director / Officer | A-Award | A | Stock Option (right to buy) | 10,962 | 12.62 | 138.3K | 10,962 | D | ↗ |
| 2025-01-02 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 11,328 | 13.13 | 148.7K | 11,328 | D | ↗ |
| 2024-12-02 | Furcht Leo | Director | M-Exempt | D | Employee Stock Option (right to buy) | 250 | 3.60 | 900.00 | 0 | D | ↗ |
| 2024-10-23 | Buller Richard E | Director | S-Sale | D | Common Stock | 350 | 16.25 | 5.7K | 6,681 | I | ↗ |
| 2024-08-23 | Buller Richard E | Director | S-Sale | D | Common Stock | 350 | 16.95 | 5.9K | 7,031 | — | ↗ |
| 2024-08-20 | Sullivan Brian F. | Director / Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 17.04 | 4.26M | 250,000 | — | ↗ |
| 2024-08-20 | Laing Lance G. | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 17.04 | 1.70M | 100,000 | — | ↗ |
| 2024-08-20 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 17.04 | 1.36M | 80,000 | — | ↗ |
| 2024-06-24 | Murphy Polly A. | Director | G-Gift | D | Stock Option (right to buy) | 16,300 | 8.31 | 135.5K | 0 | D | ↗ |
| 2024-06-21 | Buller Richard E | Director | S-Sale | D | Common Stock | 350 | 15.68 | 5.5K | 7,381 | — | ↗ |
| 2024-06-10 | NIGON RICHARD | Director | X-InTheMoney | A | Common Stock | 5,061 | 9.50 | 48.1K | 101,093 | — | ↗ |
| 2024-06-04 | NIGON RICHARD | Director | A-Award | A | Stock Option (right to buy) | 8,153 | 14.83 | 120.9K | 8,153 | — | ↗ |
| 2024-06-04 | Murphy Polly A. | Director | A-Award | A | Stock Option (right to buy) | 8,153 | 14.83 | 120.9K | 8,153 | — | ↗ |
| 2024-06-04 | Furcht Leo | Director | A-Award | A | Stock Option (right to buy) | 8,153 | 14.83 | 120.9K | 8,153 | — | ↗ |
| 2024-06-04 | Dalvey David | Director | A-Award | A | Stock Option (right to buy) | 8,153 | 14.83 | 120.9K | 8,153 | — | ↗ |
| 2024-06-04 | Buller Richard E | Director | A-Award | A | Common Stock | 1,079 | 0.00 | — | 6,852 | — | ↗ |
| 2024-05-22 | Buller Richard E | Director | G-Gift | D | Common Stock | 1,958 | 0.00 | — | 5,773 | — | ↗ |
| 2024-04-26 | Sullivan Brian F. | Director / Officer / 10% Owner | G-Gift | A | Common Stock | 45,025 | 0.00 | — | 908,372 | — | ↗ |
| 2024-04-24 | Buller Richard E | Director | S-Sale | D | Common Stock | 350 | 17.06 | 6.0K | 7,731 | — | ↗ |
| 2024-04-08 | Buller Richard E | Director | G-Gift | A | Stock Option (right to buy) | 12,654 | 5.10 | 64.5K | 12,654 | — | ↗ |
| 2024-03-18 | Sullivan Brian F. | Director / Officer / 10% Owner | G-Gift | A | Common Stock | 765,897 | 0.00 | — | 765,897 | — | ↗ |
| 2024-02-21 | Buller Richard E | Director | S-Sale | D | Common Stock | 350 | 14.15 | 5.0K | 8,081 | — | ↗ |
| 2024-02-13 | Laing Lance G. | Director / Officer | A-Award | A | Stock Option (right to buy) | 7,765 | 15.03 | 116.7K | 7,765 | — | ↗ |
| 2024-02-13 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 5,530 | 15.03 | 83.1K | 5,530 | — | ↗ |
| 2024-01-30 | Sullivan Brian F. | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 85,000 | 0.00 | — | 1,198,296 | — | ↗ |
| 2024-01-02 | Sullivan Brian F. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 84,000 | 14.78 | 1.24M | 84,000 | — | ↗ |
| 2023-12-27 | Sullivan Brian F. | Director / Officer / 10% Owner | G-Gift | A | Common Stock | 870,000 | 0.00 | — | 870,000 | — | ↗ |
| 2023-12-20 | Buller Richard E | Director | S-Sale | D | Common Stock | 350 | 14.37 | 5.0K | 8,431 | — | ↗ |
| 2023-12-15 | Dalvey David | Director | S-Sale | D | Common Stock | 2,940 | 14.57 | 42.8K | 225,000 | — | ↗ |
| 2023-12-14 | Dalvey David | Director | S-Sale | D | Common Stock | 5,000 | 14.75 | 73.8K | 227,940 | — | ↗ |
| 2023-12-13 | Dalvey David | Director | S-Sale | D | Common Stock | 5,000 | 14.50 | 72.5K | 232,940 | — | ↗ |
| 2023-12-12 | Dalvey David | Director | S-Sale | D | Common Stock | 2,060 | 14.61 | 30.1K | 237,940 | — | ↗ |
| 2023-12-08 | Dalvey David | Director | S-Sale | D | Common Stock | 5,000 | 15.00 | 75.0K | 240,000 | — | ↗ |
| 2023-12-07 | Dalvey David | Director | S-Sale | D | Common Stock | 5,000 | 14.85 | 74.3K | 245,000 | — | ↗ |
| 2023-11-28 | Furcht Leo | Director | M-Exempt | A | Common Stock | 250 | 1.60 | 400.00 | 10,500 | — | ↗ |
| 2023-10-25 | Buller Richard E | Director | S-Sale | D | Common Stock | 350 | 10.23 | 3.6K | 8,781 | — | ↗ |
| 2023-08-30 | Buller Richard E | Director | S-Sale | D | Common Stock | 350 | 9.28 | 3.2K | 9,131 | — | ↗ |
| 2023-08-25 | Sullivan Brian F. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 180,000 | 9.89 | 1.78M | 180,000 | — | ↗ |
| 2023-08-25 | Laing Lance G. | Director / Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 9.89 | 1.24M | 125,000 | — | ↗ |
| 2023-08-25 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 9.89 | 593.4K | 60,000 | — | ↗ |
| 2023-08-23 | Buller Richard E | Director | S-Sale | D | Common Stock | 300 | 9.82 | 2.9K | 9,481 | — | ↗ |
| 2023-06-23 | Buller Richard E | Director | S-Sale | D | Common Stock | 300 | 11.79 | 3.5K | 9,781 | — | ↗ |
| 2023-05-23 | Buller Richard E | Director | S-Sale | D | Common Stock | 75 | 11.10 | 832.50 | 10,081 | — | ↗ |
| 2023-05-22 | Furcht Leo | Director | P-Purchase | A | Common Stock | 10,000 | 10.32 | 103.2K | 10,250 | — | ↗ |
| 2023-05-22 | Buller Richard E | Director | S-Sale | D | Common Stock | 100 | 10.50 | 1.1K | 10,156 | — | ↗ |
| 2023-05-19 | Buller Richard E | Director | S-Sale | D | Common Stock | 250 | 9.85 | 2.5K | 10,256 | — | ↗ |
| 2023-05-15 | NIGON RICHARD | Director | A-Award | A | Stock Option (right to buy) | 11,645 | 9.58 | 111.6K | 11,645 | — | ↗ |
| 2023-05-15 | Murphy Polly A. | Director | A-Award | A | Stock Option (right to buy) | 11,645 | 9.58 | 111.6K | 11,645 | — | ↗ |
| 2023-05-15 | Furcht Leo | Director | A-Award | A | Stock Option (right to buy) | 11,645 | 9.58 | 111.6K | 11,645 | — | ↗ |
| 2023-05-15 | Dalvey David | Director | A-Award | A | Stock Option (right to buy) | 11,645 | 9.58 | 111.6K | 11,645 | — | ↗ |
| 2023-05-15 | Buller Richard E | Director | A-Award | A | Common Stock | 1,958 | 0.00 | — | 10,506 | — | ↗ |
| 2023-04-21 | Buller Richard E | Director | S-Sale | D | Common Stock | 300 | 9.70 | 2.9K | 8,548 | — | ↗ |
| 2023-02-21 | Buller Richard E | Director | S-Sale | D | Common Stock | 300 | 11.40 | 3.4K | 8,848 | — | ↗ |
| 2023-02-16 | Sullivan Brian F. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 69,760 | 11.55 | 805.7K | 69,760 | — | ↗ |
| 2023-02-16 | Laing Lance G. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 9,156 | 11.55 | 105.8K | 9,156 | — | ↗ |
| 2023-02-16 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 5,069 | 11.55 | 58.5K | 5,069 | — | ↗ |
| 2022-12-19 | Buller Richard E | Director | S-Sale | D | Common Stock | 300 | 11.11 | 3.3K | 9,148 | — | ↗ |
| 2022-12-09 | Sullivan Brian F. | Officer | P-Purchase | A | Common Stock | 260,869 | 5.75 | 1.50M | 3,016,643 | — | ↗ |
| 2022-11-29 | Furcht Leo | Director | M-Exempt | A | Stock Option (right to buy) | 250 | 0.00 | — | 0 | — | ↗ |
| 2022-11-22 | Murphy Polly A. | Director | P-Purchase | A | Common Stock | 5,000 | 9.68 | 48.4K | 5,000 | — | ↗ |
| 2022-10-20 | Buller Richard E | Director | S-Sale | D | Common Stock | 300 | 9.97 | 3.0K | 9,448 | — | ↗ |
| 2022-09-12 | Murphy Polly A. | Director | A-Award | A | Stock Option (right to buy) | 16,300 | 8.31 | 135.5K | 16,300 | — | ↗ |
| 2022-09-09 | NIGON RICHARD | Director | P-Purchase | A | Common Stock | 5,000 | 8.99 | 44.9K | 96,032 | — | ↗ |
| 2022-08-30 | Buller Richard E | Director | S-Sale | D | Common Stock | 100 | 10.02 | 1.0K | 9,748 | — | ↗ |
| 2022-08-26 | Buller Richard E | Director | S-Sale | D | Common Stock | 150 | 9.95 | 1.5K | 9,848 | — | ↗ |
| 2022-08-25 | Buller Richard E | Director | S-Sale | D | Common Stock | 200 | 10.05 | 2.0K | 9,998 | — | ↗ |
| 2022-08-19 | Buller Richard E | Director | S-Sale | D | Common Stock | 300 | 8.95 | 2.7K | 10,198 | — | ↗ |
| 2022-06-24 | Buller Richard E | Director | S-Sale | D | Common Stock | 300 | 9.47 | 2.8K | 10,498 | — | ↗ |
| 2022-05-25 | NIGON RICHARD | Director | P-Purchase | A | Common Stock | 754 | 5.94 | 4.5K | 91,032 | — | ↗ |
| 2022-05-23 | Buller Richard E | Director | S-Sale | D | Common Stock | 750 | 6.24 | 4.7K | 10,798 | — | ↗ |
| 2022-05-19 | Buller Richard E | Director | S-Sale | D | Common Stock | 250 | 5.65 | 1.4K | 11,548 | — | ↗ |
| 2022-05-17 | Sullivan Brian F. | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-05-17 | NIGON RICHARD | Director | A-Award | A | Stock Option (right to buy) | 24,449 | 0.00 | — | 24,449 | — | ↗ |
| 2022-05-17 | Laing Lance G. | Officer | A-Award | A | Stock Option (right to buy) | 3,215 | 0.00 | — | 3,215 | — | ↗ |
| 2022-05-17 | Hahne Vicky | Officer | A-Award | A | Stock Option (Right to Buy) | 31,930 | 0.00 | — | 31,930 | — | ↗ |
| 2022-05-17 | Furcht Leo | Director | D-Return | D | Stock Option (right to buy) | 5,054 | 0.00 | — | 0 | — | ↗ |
| 2022-05-17 | Dalvey David | Director | A-Award | A | Stock Option (right to buy) | 8,200 | 5.50 | 45.1K | 8,200 | — | ↗ |
| 2022-05-17 | Buller Richard E | Director | A-Award | A | Stock Option (right to buy) | 4,555 | 0.00 | — | 4,555 | — | ↗ |
| 2022-05-15 | Sullivan Brian F. | Officer | P-Purchase | A | Warrants (right to buy) | 10,434 | 0.00 | — | 10,434 | — | ↗ |
| 2022-04-20 | Buller Richard E | Director | S-Sale | D | Common Stock | 300 | 7.34 | 2.2K | 8,525 | — | ↗ |
| 2021-11-22 | Buller Richard E | Director | S-Sale | D | Common Stock | 250 | 15.55 | 3.9K | 8,825 | — | ↗ |
| 2021-11-19 | Buller Richard E | Director | S-Sale | D | Common Stock | 250 | 16.15 | 4.0K | 9,075 | — | ↗ |
| 2021-10-27 | Sullivan Brian F. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 6,569 | 17.19 | 112.9K | 6,569 | — | ↗ |
| 2021-10-27 | Laing Lance G. | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,877 | 17.19 | 32.3K | 1,877 | — | ↗ |
| 2021-10-27 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 821 | 17.19 | 14.1K | 821 | — | ↗ |
| 2021-08-11 | Sullivan Brian F. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 17,000 | 20.04 | 340.7K | 17,000 | — | ↗ |
| 2021-08-11 | Laing Lance G. | Director / Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 20.04 | 400.8K | 20,000 | — | ↗ |
| 2021-08-11 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 15,000 | 20.04 | 300.6K | 15,000 | — | ↗ |
| 2021-05-12 | NIGON RICHARD | Director | A-Award | A | Stock Option (right to buy) | 4,619 | 26.99 | 124.7K | 4,619 | — | ↗ |
| 2021-05-12 | Furcht Leo | Director | A-Award | A | Stock Option (right to buy) | 4,619 | 26.99 | 124.7K | 4,619 | — | ↗ |
| 2021-05-12 | Dalvey David | Director | A-Award | A | Stock Option (right to buy) | 2,310 | 26.99 | 62.3K | 2,310 | — | ↗ |
| 2021-05-12 | Buller Richard E | Director | A-Award | A | Stock Option (right to buy) | 2,310 | 26.99 | 62.3K | 2,310 | — | ↗ |
| 2021-04-12 | Sullivan Brian F. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 13,509 | 27.94 | 377.4K | 13,509 | — | ↗ |
| 2021-04-12 | Laing Lance G. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 6,754 | 27.94 | 188.7K | 6,754 | — | ↗ |
| 2021-04-12 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 3,806 | 27.94 | 106.3K | 3,806 | — | ↗ |
| 2021-03-18 | Sullivan Brian F. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 11,889 | 15.92 | 189.3K | 11,889 | — | ↗ |
| 2021-03-18 | Laing Lance G. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 2,973 | 15.92 | 47.3K | 2,973 | — | ↗ |
| 2021-03-18 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 1,204 | 15.92 | 19.2K | 1,204 | — | ↗ |
| 2021-02-02 | Sullivan Brian F. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 12,859 | 14.84 | 190.8K | 12,859 | — | ↗ |
| 2021-02-02 | Laing Lance G. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 3,215 | 14.84 | 47.7K | 3,215 | — | ↗ |
| 2021-02-02 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 1,301 | 14.84 | 19.3K | 1,301 | — | ↗ |
| 2020-12-28 | Sullivan Brian F. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 11,081 | 10.35 | 114.7K | 11,081 | — | ↗ |
| 2020-12-28 | Laing Lance G. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 2,771 | 10.35 | 28.7K | 2,771 | — | ↗ |
| 2020-12-28 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 1,122 | 10.35 | 11.6K | 1,122 | — | ↗ |
| 2020-08-12 | Sullivan Brian F. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 20,000 | 5.90 | 118.0K | 20,000 | — | ↗ |
| 2020-08-12 | Laing Lance G. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 20,000 | 5.90 | 118.0K | 20,000 | — | ↗ |
| 2020-08-12 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 5.90 | 59.0K | 10,000 | — | ↗ |
| 2020-05-14 | NIGON RICHARD | Director | A-Award | A | Stock Option (right to buy) | 25,308 | 5.10 | 129.1K | 25,308 | — | ↗ |
| 2020-05-14 | Furcht Leo | Director | A-Award | A | Stock Option (right to buy) | 25,308 | 5.10 | 129.1K | 25,308 | — | ↗ |
| 2020-05-14 | Dalvey David | Director | A-Award | A | Stock Option (right to buy) | 12,654 | 5.10 | 64.5K | 12,654 | — | ↗ |
| 2020-05-14 | Buller Richard E | Director | A-Award | A | Stock Option (right to buy) | 12,654 | 5.10 | 64.5K | 12,654 | — | ↗ |
| 2019-12-03 | Buller Richard E | Director | A-Award | A | Stock Option (right to buy) | 4,555 | 10.68 | 48.6K | 4,555 | — | ↗ |
| 2019-08-12 | Sullivan Brian F. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 4,985 | 19.72 | 98.3K | 4,985 | — | ↗ |
| 2019-08-12 | Laing Lance G. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 50,000 | 19.72 | 986.0K | 50,000 | — | ↗ |
| 2019-08-12 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 3,000 | 19.72 | 59.2K | 3,000 | — | ↗ |
| 2019-05-16 | NIGON RICHARD | Director | A-Award | A | Stock Option (right to buy) | 5,054 | 22.45 | 113.5K | 5,054 | — | ↗ |
| 2019-05-16 | Furcht Leo | Director | A-Award | A | Stock Option (right to buy) | 5,054 | 22.45 | 113.5K | 5,054 | — | ↗ |
| 2019-05-16 | Dalvey David | Director | A-Award | A | Stock Option (right to buy) | 5,054 | 22.45 | 113.5K | 5,054 | — | ↗ |
| 2019-05-16 | Cronin Maureen Therese | Director | A-Award | A | Stock Option (right to buy) | 5,054 | 22.45 | 113.5K | 5,054 | — | ↗ |
| 2018-10-17 | Sullivan Brian F. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 14,675 | 25.77 | 378.2K | 14,675 | — | ↗ |
| 2018-10-17 | Laing Lance G. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 1,834 | 25.77 | 47.3K | 1,834 | — | ↗ |
| 2018-10-17 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 932 | 25.77 | 24.0K | 932 | — | ↗ |
| 2018-09-11 | NIGON RICHARD | Director | P-Purchase | A | Common Stock | 9,747 | 22.31 | 217.5K | 90,278 | — | ↗ |
| 2018-08-13 | Sullivan Brian F. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 3,769 | 26.00 | 98.0K | 3,769 | — | ↗ |
| 2018-07-05 | Hahne Vicky | Officer | A-Award | A | Stock Option (right to buy) | 3,000 | 23.48 | 70.4K | 3,000 | — | ↗ |
| 2018-05-31 | NIGON RICHARD | Director | P-Purchase | A | Common Stock | 10,000 | 19.04 | 190.4K | 80,531 | — | ↗ |
| 2018-05-14 | NIGON RICHARD | Director | A-Award | A | Stock Option (right to buy) | 3,201 | 19.45 | 62.3K | 3,201 | — | ↗ |
| 2018-05-14 | Dalvey David | Director | A-Award | A | Stock Option (right to buy) | 3,201 | 19.45 | 62.3K | 3,201 | — | ↗ |
| 2018-05-14 | Cronin Maureen Therese | Director | A-Award | A | Common Stock | 2,571 | 0.00 | — | 7,821 | — | ↗ |
| 2017-11-28 | NIGON RICHARD | Director | P-Purchase | A | Common Stock | 7,500 | 17.48 | 131.1K | 70,531 | — | ↗ |
| 2017-11-21 | NIGON RICHARD | Director | P-Purchase | A | Common Stock | 1,000 | 18.15 | 18.2K | 63,031 | — | ↗ |
| 2017-11-20 | NIGON RICHARD | Director | P-Purchase | A | Common Stock | 7,500 | 17.20 | 129.0K | 62,031 | — | ↗ |
| 2017-10-26 | Cronin Maureen Therese | Director | A-Award | A | Common Stock | 5,250 | 0.00 | — | 5,250 | — | ↗ |
| 2017-10-19 | NIGON RICHARD | Director | A-Award | A | Stock Option (right to buy) | 8,200 | 16.23 | 133.1K | 8,200 | — | ↗ |
| 2017-10-19 | Dalvey David | Director | A-Award | A | Stock Option (right to buy) | 8,200 | 16.23 | 133.1K | 8,200 | — | ↗ |
| 2017-09-19 | SULLIVAN BRIAN F | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,755,774 | — | ↗ |
| 2017-09-19 | NIGON RICHARD | Director | — | D | Warrants (right to buy) | 1,429 | 8.42 | 12.0K | 0 | — | ↗ |
| 2017-09-19 | Laing Lance G. | Director / Officer / 10% Owner | — | D | Stock Option (right to buy) | 16,125 | 8.40 | 135.5K | 0 | — | ↗ |
| 2017-09-19 | Hahne Vicky | Officer | — | D | Stock Option (right to buy) | 37,500 | 8.40 | 315.0K | 0 | — | ↗ |
| 2017-09-19 | Dalvey David | Director | — | I | Common Stock | 0 | 0.00 | — | 250,000 | — | ↗ |
| 2017-09-19 | Cronin Maureen Therese | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
48.34M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Brian F. Sullivan Chairman and Chief Executive Officer | 577.1K | — | — | 15.43M | 368.1K | — | 16.37M | 94.23% | ↗ |
| 2 | 2025 | Lance G. Laing Chief Science Officer | 472.6K | — | — | 3.52M | 201.2K | — | 4.19M | 83.93% | ↗ |
| 3 | 2025 | Vicky Hahne Chief Financial Officer | 419.6K | — | — | 2.81M | 178.5K | — | 3.41M | 82.47% | ↗ |
| 4 | 2024 | Brian F. Sullivan Chairman and Chief Executive Officer | 525.0K | 47.3K | — | 5.75M | 265.9K | — | 6.59M | 87.27% | ↗ |
| 5 | 2024 | Lance G. Laing Chief Science Officer | 351.5K | 13.5K | — | 1.26M | 76.2K | — | 1.70M | 74.09% | ↗ |
| 6 | 2024 | Vicky Hahne Chief Financial Officer | 267.5K | 22.1K | — | 937.5K | 124.1K | — | 1.35M | 69.39% | ↗ |
| 7 | 2023 | Brian F. Sullivan Chairman and Chief Executive Officer | 209.6K | — | — | 1.26M | 268.5K | — | 1.74M | 72.49% | ↗ |
| 8 | 2023 | Lance G. Laing Chief Science Officer | 312.6K | — | — | 1.09M | 77.0K | — | 1.48M | 73.75% | ↗ |
| 9 | 2023 | Vicky Hahne Chief Financial Officer | 226.8K | — | — | 617.2K | 54.8K | — | 898.7K | 68.67% | ↗ |
| 10 | 2022 | Brian F. Sullivan Chairman and Chief Executive Officer | 105.8K | — | — | 1.71M | — | — | 1.81M | 94.17% | ↗ |
| 11 | 2022 | Lance G. Laing Chief Science Officer | 325.4K | — | — | 351.8K | 72.2K | — | 749.4K | 46.94% | ↗ |
| 12 | 2022 | Vicky Hahne Chief Financial Officer | 210.0K | — | — | 199.5K | 40.0K | — | 449.5K | 44.38% | ↗ |
| 13 | 2021 | Brian F. Sullivan Chairman and Chief Executive Officer | 259.6K | — | — | 1.07M | — | — | 1.33M | 80.41% | ↗ |
| 14 | 2021 | Lance G. Laing Chief Science Officer | 344.4K | — | — | 477.9K | 103.5K | — | 925.8K | 51.62% | ↗ |
| 15 | 2021 | Vicky Hahne Chief Financial Officer | 191.9K | — | — | 306.3K | 42.6K | — | 540.9K | 56.64% | ↗ |
| 16 | 2020 | Brian F. Sullivan Chairman and Chief Executive Officer | 250.0K | — | — | 219.0K | — | — | 469.0K | 46.69% | ↗ |
| 17 | 2020 | Lance G. Laing Chief Science Officer | 315.0K | — | — | 97.0K | 18.9K | — | 430.9K | 22.52% | ↗ |
| 18 | 2020 | Vicky Hahne Chief Financial Officer | 170.0K | — | — | 46.7K | 7.7K | — | 224.4K | 20.82% | ↗ |
| 19 | 2019 | Brian F. Sullivan Chairman and Chief Executive Officer | 250.0K | — | — | 741.5K | — | — | 991.5K | 74.79% | ↗ |
| 20 | 2019 | Lance G. Laing Chief Science Officer | 315.0K | — | — | 676.3K | — | — | 991.3K | 68.22% | ↗ |
| 21 | 2019 | Vicky Hahne Chief Financial Officer | 164.6K | — | — | 40.6K | — | — | 205.2K | 19.78% | ↗ |
| 22 | 2018 | Brian F. Sullivan Chairman and Chief Executive Officer | 250.0K | — | — | 314.2K | — | — | 564.2K | 55.69% | ↗ |
| 23 | 2018 | Lance G. Laing Chief Science Officer | 285.5K | — | — | 31.1K | 94.5K | — | 411.1K | 7.58% | ↗ |
| 24 | 2018 | Vicky Hahne Chief Financial Officer | 154.6K | — | — | 62.5K | 25.0K | — | 242.2K | 25.83% | ↗ |
| 25 | 2017 | Brian F. Sullivan Chairman and Chief Executive Officer | 231.8K | — | — | 258.7K | — | — | 490.5K | 52.74% | ↗ |
| 26 | 2017 | Lance G. Laing Chief Science Officer | 241.6K | — | — | 174.5K | 23.0K | — | 439.1K | 39.74% | ↗ |
| 27 | 2017 | Vicky Hahne Chief Financial Officer | 67.9K | — | — | 315.0K | — | — | 382.9K | 82.27% | ↗ |
| 28 | 2017 | Vicky Hahne Chief Financial Officer | 67.9K | — | — | 315.0K | — | — | 382.9K | 82.27% | ↗ |
| 29 | 2016 | Lance G. Laing Chief Science Officer | 214.1K | — | — | — | — | — | 214.1K | 0.00% | ↗ |
| 30 | 2016 | Brian F. Sullivan Chairman and Chief Executive Officer | 214.1K | — | — | — | — | — | 214.1K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brian F. Sullivan | Co-Founder, Chairman & Chief Executive Officer | 945.2K | male |
| Lance G. Laing | Co-Founder, Chief Science Officer, Vice President, Secretary & Director | 673.8K | — |
| Vicky Hahne | Chief Financial Officer | 598.1K | female |
| Brent Eilefson | General Counsel | — | male |
| Sheri Smith | Acting Head of Clinical Operations | — | female |
| Jodi Sievers | Head of Investor Relations & Corporate Communications | — | female |
| Eldon C. Mayer | Chief Commercial Officer | — | male |
| Igor Gorbatchevsky | Chief Medical Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CELC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
